Cargando…

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications

Fibrosing interstitial lung disease (ILD) is one of the most important causes of morbidity and mortality in patients with connective tissue diseases (CTDs), which include systemic sclerosis, rheumatoid arthritis, Sjögren’s syndrome, idiopathic inflammatory myositis and systemic lupus erythematosus....

Descripción completa

Detalles Bibliográficos
Autores principales:	Erre, Gian Luca, Sebastiani, Marco, Manfredi, Andreina, Gerratana, Elisabetta, Atzeni, Fabiola, Passiu, Giuseppe, Mangoni, Arduino A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813437/ https://www.ncbi.nlm.nih.gov/pubmed/33505482 http://dx.doi.org/10.7573/dic.2020-8-6

Ejemplares similares

Efficacy, Safety, and Tolerability of Treatments for Systemic Sclerosis-Related Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis
por: Erre, Gian Luca, et al.
Publicado: (2020)

Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)
por: Jee, Adelle S., et al.
Publicado: (2017)

Current therapeutic strategies in connective tissue disease-related interstitial lung disease: introduction to the special issue
por: Erre, Gian Luca, et al.
Publicado: (2021)

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
por: Spagnolo, Paolo, et al.
Publicado: (2021)

Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease
por: Vacchi, Caterina, et al.
Publicado: (2021)

Vitamin D levels are prognostic factors for connective tissue disease associated interstitial lung disease (CTD-ILD)
por: Gao, Yujuan, et al.
Publicado: (2020)

Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers
por: Cerro Chiang, Giuliana, et al.
Publicado: (2023)

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
por: Shumar, John N., et al.
Publicado: (2021)

Association of Red Blood Cell Distribution Width Levels with Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)
por: Shi, Shenyun, et al.
Publicado: (2021)

Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management
por: Yoo, Hongseok, et al.
Publicado: (2020)

Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management
por: Yoo, Hongseok, et al.
Publicado: (2022)

Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review
por: Cassone, Giulia, et al.
Publicado: (2021)

Meta-Analysis of Asymmetric Dimethylarginine Concentrations in Rheumatic Diseases
por: Erre, Gian Luca, et al.
Publicado: (2019)

Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience
por: Boutel, Maria, et al.
Publicado: (2023)

Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases
por: Nucera, Valeria, et al.
Publicado: (2021)

Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)
por: Gagiannis, Daniel, et al.
Publicado: (2020)

The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD
por: Kolb, Martin, et al.
Publicado: (2022)

Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study
por: Cassone, Giulia, et al.
Publicado: (2020)

Study protocol for connective tissue disease-associated interstitial lung disease trial (TEL-CTD-ILD): A randomized controlled trial of a home-based telemonitoring of treatment effects
por: Małysiak-Szpond, Sylwia, et al.
Publicado: (2022)

ChILD – Children's interstitial lung disease
Publicado: (2018)

CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
por: Zanatta, Elisabetta, et al.
Publicado: (2023)

Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages
por: Mangoni, Arduino A., et al.
Publicado: (2021)

Diagnostic accuracy of different blood cells-derived indexes in rheumatoid arthritis: A cross-sectional study
por: Erre, Gian Luca, et al.
Publicado: (2020)

Oxidative Stress Biomarkers and Peripheral Endothelial Dysfunction in Rheumatoid Arthritis: A Monocentric Cross-Sectional Case-Control Study
por: Bassu, Stefania, et al.
Publicado: (2020)

Interstitial lung disease (ILD) in India: Insights and lessons from the prospective, landmark ILD-India registry
por: Raghu, Ganesh, et al.
Publicado: (2016)

Impact of progressive fibrosing interstitial lung disease (ILD) in ILD patients complicated with secondary spontaneous pneumothorax
por: Yamakawa, Hideaki, et al.
Publicado: (2021)

Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
por: Cottin, Vincent, et al.
Publicado: (2019)

Children’s Interstitial and Diffuse Lung Diseases (ChILD) in 2020
por: Ferraro, Valentina Agnese, et al.
Publicado: (2020)

Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
por: Copeland, Carla R., et al.
Publicado: (2021)

Syndecan-2 regulates PAD2 to exert antifibrotic effects on RA-ILD fibroblasts
por: Tsoyi, Konstantin, et al.
Publicado: (2022)

An unusual case of interstitial lung disease: Revisiting peribronchiolar metaplasia interstitial lung disease (PBM‐ILD)
por: Jung, Flora, et al.
Publicado: (2023)

Surfactant Metabolism Dysfunction and Childhood Interstitial Lung Disease (chILD)
por: McFetridge, Lynne, et al.
Publicado: (2009)

Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review
por: Vacchi, Caterina, et al.
Publicado: (2020)

Are There Differences in Inflammatory and Fibrotic Pathways between IPAF, CTD-ILDs, and IIPs? A Single-Center Pilot Study
por: Rzepka-Wrona, Patrycja, et al.
Publicado: (2022)

Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease
por: Scirocco, Chiara, et al.
Publicado: (2020)

Antifibrotic in interstitial lung diseases: When, where, and how long?
por: Rai, Deependra K., et al.
Publicado: (2022)

ILD-GAP Combined with the Charlson Comorbidity Index Score (ILD-GAPC) as a Prognostic Prediction Model in Patients with Interstitial Lung Disease
por: Fujii, Hiroaki, et al.
Publicado: (2023)

ILDgenDB: integrated genetic knowledge resource for interstitial lung diseases (ILDs)
por: Mishra, Smriti, et al.
Publicado: (2018)

Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians
por: Althobiani, Malik, et al.
Publicado: (2021)

Diagnosis, Clinical Features and Management of Interstitial Lung Diseases in Rheumatic Disorders: Still a Long Journey
por: Sebastiani, Marco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0rjp4q4sr20vv09o2sjj391k16